Trial Profile
A Prospective,Multi-center, Open-labeled Phase 2 Randomized and Comparative Clinical Study of First Line Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in ⅢB/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Icotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Feb 2018 Planned primary completion date changed from 1 Jun 2017 to 31 Dec 2018.
- 27 Feb 2018 Status changed from recruiting to not yet recruiting.
- 16 May 2017 New trial record